Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02517034 · ClinicalTrials.gov registry record · NA
Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With Cancer
A NA study of Solid Neoplasm, sponsored by City of Hope Medical Center.
- Active
- Registry status
- NA
- Development phase
- 600
- Enrollment target
- 5
- Study locations
NCT02517034 is a NA study of Solid Neoplasm that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 600 participants, below the 893-participant average among 12 other Solid Neoplasm trials with a reported enrollment target (33% lower). The trial reports 5 study locations across 1 state.
The verdict
NCT02517034, a NA study of Solid Neoplasm, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 600 participants
- Enrollment target
- 5
- Study locations
Study Summary
This randomized clinical trial studies a geriatric assessment intervention in predicting chemotherapy toxicity and vulnerabilities (or weakness) in older patients with cancer. Assessing patients' functional status, comorbidities, psychological state, social support, nutritional status, and cognitive function before treatment may help identify vulnerabilities, improve care, and decrease chemotherapy side effects in older patients with cancer.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Survey Administration
- OTHER Questionnaire Administration
- OTHER Comprehensive Geriatric Assessment
Study Locations (5)
California
- City of Hope Medical Center - Duarte
- City of Hope Antelope Valley - Lancaster
- City of Hope Rancho Cucamonga - Rancho Cucamonga
- City of Hope South Pasadena - South Pasadena
- City of Hope West Covina - West Covina
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2015-08-04 |
| Est. Completion | 2026-02-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02517034
The ClinicalTrials.gov registry entry for NCT02517034 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 893-participant average among 12 other Solid Neoplasm trials with a reported enrollment target (33% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02517034 reports 5 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02517034 about?
NCT02517034 is a clinical study titled "Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With Cancer". This randomized clinical trial studies a geriatric assessment intervention in predicting chemotherapy toxicity and vulnerabilities (or weakness) in older patients with cancer. Assessing patients' functional status, comorbidities, psychological state, social support, nutritional status, and cognitive...
What is the current status of trial NCT02517034?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2015-08-04. Estimated completion is 2026-02-28.
What conditions does trial NCT02517034 study?
This clinical trial studies the following conditions: Solid Neoplasm.
What interventions are being tested in trial NCT02517034?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Survey Administration (OTHER), Questionnaire Administration (OTHER), Comprehensive Geriatric Assessment (OTHER).
Who is sponsoring clinical trial NCT02517034?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02517034 being conducted?
This trial has 5 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Movement Tracking Devices to Monitor Physical Activity in Patients Undergoing Chemotherapy
COMPLETED · NA
-
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
RECRUITING · Phase 1
-
UWCCC Molecular Tumor Board Registry
RECRUITING
-
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
ACTIVE NOT RECRUITING · Phase 2
-
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.